Holen Sie sich die Stockscreener-App
1.19
5.56%
-0.07
Handel nachbörslich:
1.17
-0.02
-1.68%
Schlusskurs vom Vortag:
$1.26
Offen:
$1.26
24-Stunden-Volumen:
278.94K
Relative Volume:
1.30
Marktkapitalisierung:
$55.48M
Einnahmen:
$42,000
Nettoeinkommen (Verlust:
$-11.44M
KGV:
-4.7753
EPS:
-0.2492
Netto-Cashflow:
$-7.93M
1W Leistung:
+19.00%
1M Leistung:
-4.80%
6M Leistung:
-35.33%
1J Leistung:
-25.63%
1-Tages-Spanne:
$1.17
$1.295
1-Wochen-Bereich:
$0.9801
$1.39
52-Wochen-Spanne:
$0.91
$3.22
Entera Bio Ltd Stock (ENTX) Company Profile
Firmenname
Entera Bio Ltd
Sektor
Branche
Telefon
972-2-532-7151
Adresse
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
1.19 | 58.74M | 42,000 | -11.44M | -7.93M | -0.2492 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-22 | Eingeleitet | Aegis Capital | Buy |
Entera Bio Ltd Aktie (ENTX) Neueste Nachrichten
Greenberg Traurig Represents Entera Bio in $10M Private Placement - National Today
Entera Bio raises $10M in private placement led by BVF Partners - Investing.com
Entera Bio puts $10M financing toward Phase 3 osteoporosis study - stocktitan.net
Market Leaders: Is Entera Bio Ltd stock risky to hold now2026 Movers & AI Enhanced Execution Alerts - baoquankhu1.vn
Entera Bio Ltd. Announces Private Placement and Securities Purchase Agreement for Phase 3 Osteoporosis Study Funding - Minichart
Entera Bio Announces $10 Million Private Placement Financing - TipRanks
Entera Bio Raises $10 Million in Private Placement With BVF Partners, Adds Registration Rights - TradingView
Entera Bio (NASDAQ: ENTX) completes private placement with BVF funds - stocktitan.net
Entera Bio submits streamlined Phase 3 protocol for oral osteoporosis drug - Investing.com
Fresh $10M gives Entera Bio runway for Phase 3 osteoporosis study - stocktitan.net
ENTX Technical Analysis & Stock Price Forecast - Intellectia AI
Entera Bio Ltd. announced that it expects to receive $10 million in funding - marketscreener.com
Net current asset value per share of Entera Bio Ltd. – LS:A2JQXP - TradingView
Stock market today: S&P 500, Dow futures gain as Trump calls Iran's new leaders 'very reasonable'—Palantir, Rezolve AI, Entera Bio in focus - MSN
Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'— PLTR, RZLV, ENTX In Focus (UPDATED) - Benzinga
Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable' - Benzinga
Stock Market Today: S&P 500, Dow Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'—Palantir, Rezolve AI, Entera Bio In FocusState Street SPDR S&P 500 ETF Trust (ARCA:SPY) - Benzinga
Phreesia, Progress Software And 3 Stocks To Watch Heading Into Monday - Sahm
Entera Bio Ltd. Advances First-in-Class Oral Peptide Therapies for Osteoporosis, Hypoparathyroidism, and Metabolic Diseases – 2026 Annual Report Highlights - Minichart
Entera Bio Reports $18.7 Million Net Loss for 2025 and $1.2 Million in Revenue - geneonline.com
Entera Bio Reports 2025 Results, Advances Oral Osteoporosis Pipeline - TipRanks
Entera Bio (NASDAQ:ENTX) Releases Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
ENTX: FDA-aligned EB613 Phase 3, pipeline advanced, net loss $11.4M, cash supports into Q3 2026 - TradingView
Entera 10-K: Revenue $0.042M, Loss Per Share $0.25 - TradingView
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Entera Bio (NASDAQ: ENTX) outlines oral osteoporosis and metabolic pipeline - Stock Titan
Entera Bio Ltd. Advances Oral Peptide Pipeline with Key FDA Submissions and Clinical Program Updates for Osteoporosis and Other Conditions - Quiver Quantitative
Entera Bio (NASDAQ: ENTX) 2025 loss widens as oral peptide pipeline advances - Stock Titan
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates - Bitget
S P Trends: Should I invest in Entera Bio Ltd before earnings2026 AllTime Highs & Capital Protection Trade Alerts - baoquankhu1.vn
Entera May Be the 1st Winner of FDA’s New Framework Redefining the Multi Billion Dollar Osteoporosis Market - The Globe and Mail
If You Invested $1,000 in Entera Bio Ltd (ENTX) - stocktitan.net
Stock List: Research Stocks from Around the World - GuruFocus
What pushed Entera Bio (ENTX) to rally nearly 16% after hours - MSN
Entera Bio (ENTX) Expected to Announce Earnings on Friday - marketbeat.com
Analyst Upgrade: Is Entera Bio Ltd stock risky to hold now2026 Winners & Losers & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Trend Review: Should I invest in Entera Bio Ltd before earnings2026 Spike Watch & Free Verified High Yield Trade Plans - baoquankhu1.vn
Energy Moves: Can Entera Bio Ltd weather a recession2026 Opening Moves & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Entera Takes Final Step Towards Phase 3, Accelerating Timeline f - GuruFocus
Performance Recap: Is Entera Bio Ltd stock risky to hold now2026 Highlights & Daily Market Momentum Tracking - baoquankhu1.vn
Entera Takes Final Step Towards Phase 3, Accelerating Timeline for First Oral Anabolic Osteoporosis Therapy - TipRanks
Entera Bio (NASDAQ:ENTX) Director Geno Germano Purchases 20,000 Shares - MarketBeat
Insider Buying: Geno Germano Acquires Additional Shares of Enter - GuruFocus
Entera Bio (ENTX) director buys 20,000 shares in open market - Stock Titan
Insider Buying: Entera Bio (NASDAQ:ENTX) Director Buys 10,000 Shares of Stock - MarketBeat
Director Sean Ellis buys 10,000 Entera Bio (ENTX) shares on market - Stock Titan
Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX) - TipRanks
Entera Bio (NASDAQ:ENTX) Stock Price Down 3%Here's What Happened - MarketBeat
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis - Bitget
ENTX SEC FilingsEntera Bio Ltd 10-K, 10-Q, 8-K Forms - stocktitan.net
Entera Bio Submits Streamlined Phase 3 Plan for EB613 - TipRanks
Finanzdaten der Entera Bio Ltd-Aktie (ENTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Entera Bio Ltd-Aktie (ENTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ellis Sean | Director |
Mar 05 '26 |
Buy |
1.23 |
10,000 |
12,300 |
188,098 |
| Rubin Steven D | Director |
Feb 12 '26 |
Buy |
1.49 |
5,000 |
7,450 |
15,000 |
| Rubin Steven D | Director |
Feb 09 '26 |
Buy |
1.20 |
10,000 |
12,000 |
10,000 |
| Ellis Sean | Director |
Feb 09 '26 |
Buy |
1.24 |
18,000 |
22,320 |
178,098 |
| Toledano Miranda Jayne | Chief Executive Officer |
Dec 29 '25 |
Buy |
1.81 |
11,000 |
19,912 |
426,575 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):